3 Magnificent Growth Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/19/3-magnificent-growth-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 19, 2024 - These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.
0
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
https://www.fool.com/investing/2024/03/17/3-unstoppable-stocks-you-can-buy-now-without-any/?source=iedfolrf0000001
Mar 17, 2024 - There's no need for delays in buying these great stocks.
0
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
https://www.fool.com/investing/2024/04/09/this-growth-stock-is-one-step-closer-to-launching/?source=iedfolrf0000001
Apr 09, 2024 - This innovative machine rolls on.
0
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
https://www.fool.com/investing/2024/04/20/2-everlasting-big-pharma-stocks-to-buy-today-and/?source=iedfolrf0000001
Apr 20, 2024 - These stocks probably won't be getting much cheaper.
0
bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD
https://www.zacks.com/stock/news/2196255/bluebird-blue-down-despite-fda-nod-to-gene-therapy-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196255
Dec 11, 2023 - bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
0
CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy
https://www.zacks.com/stock/news/2196180/crispr-crsp-vertex-fall-despite-fda-nod-to-scd-drug-casgevy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196180
Dec 11, 2023 - CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.
0
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197830
Dec 14, 2023 - Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
0
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
https://www.zacks.com/stock/news/2199442/vertex-vrtx-crispr-get-positive-chmp-opinion-for-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199442
Dec 18, 2023 - Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
0
Top Analyst Reports for Alphabet, Comcast & NextEra Energy
https://www.zacks.com/commentary/2201007/top-analyst-reports-for-alphabet-comcast-nextera-energy?cid=CS-ZC-FT-research_daily-2201007
Dec 21, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Comcast Corp. (CMCSA) and NextEra Energy, Inc. (NEE).
0
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
https://www.zacks.com/stock/news/2207133/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2207133
Jan 08, 2024 - Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0